Truist boosts target for Labcorp stock to USD 365.00

Published on 10/15/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp reports on October 28, 2026. Labcorp stock costs EUR 287.00 on October 15, 2026 at 7:48 p.m. CEST.

Analyst view and earnings date

Truist Financial raised its Labcorp target to USD 365.00 on September 21, 2026.
Labcorp reported USD 3.73 billion in second-quarter revenue, up 5.80 percent year over year.
Labcorp stock costs EUR 287.00 at Lang & Schwarz on October 15, 2026 at 7:48 p.m. CEST.
Labcorp will release third-quarter results on October 28, 2026.

Modernes Diagnostiklabor mit Technikern in weißen Kitteln an automatisierten Analysegeräten — Labcorp (ISIN US50540R4092) betreibt moderne klinische Labore mit Technikern und automatisierten Diagnosegeräten hinter Glasfassaden, Illustration mit AI erstellt.

Truist Financial boosted its Labcorp target from USD 350.00 to USD 365.00 in a research note dated September 21, 2026, according to MarketBeat. Against Labcorp's USD 322.83 Nasdaq price at 1:56 p.m. ET on October 15, 2026, the new target is 13.06 percent higher. Labcorp stock was trading at EUR 287.00 at Lang & Schwarz on October 15, 2026 at 7:48 p.m. CEST.

Revenue growth sets the baseline

Labcorp generated USD 3.73 billion in second-quarter revenue, up 5.80 percent from the same quarter a year earlier. The company also reported diluted earnings per share of USD 3.64 and net income of USD 298.70 million for the period. The standardized quarterly figures are for the period ended June 30, 2026.

MarketBeat reported that second-quarter revenue exceeded expectations of USD 3.71 billion, while earnings per share exceeded consensus of USD 4.78 in the same report. The comparison gives the upcoming release a clear operating benchmark.

Price position and trading range

Labcorp's Nasdaq quote was USD 322.83 at 1:56 p.m. ET on October 15, 2026, up 1.73 percent from the prior close of USD 317.34. The 52-week range was USD 244.52 to USD 341.80, placing the quote 5.55 percent below the high. Trading volume was 185,457 shares against an average of 737,107.

For the broader annual picture, Labcorp stock was up 27.00 percent in 2026, according to CNBC. The company enters the results date with a 5.40 percent to 6.30 percent full-year revenue-growth outlook.

Valuation and reporting date

Labcorp had a market capitalization of USD 26.2 billion, a P/E ratio of 26.70 and a dividend yield of 0.01 percent as of October 15, 2026. Its third-quarter results are scheduled for October 28, 2026, before the Nasdaq open, according to Labcorp.

Comparison with peers

Labcorp (NYSE, USD): plus 1.73 percent, P/E 26.70, market capitalization USD 26.2 billion

Quest Diagnostics (NYSE, USD): plus 1.60 percent, P/E 25.17, market capitalization USD 26.2 billion

Charles River Laboratories (NYSE, USD): plus 1.64 percent, P/E minus 63.39, market capitalization USD 14.8 billion

Investor calendar remains central

The October 28 reporting date is the next scheduled test for Labcorp's outlook and earnings trajectory. The combination of a USD 365.00 Truist target, a 27.00 percent 2026 gain and a quote 5.55 percent below its annual high leaves the upcoming results as the next concrete valuation checkpoint.

The further course of trading is shown by the continuously updated real-time quote of Labcorp stock.